

Document No. 07a

Invitation to offer for NHS National Generic Pharmaceuticals - Dasatinib and Paliperidone Injection

Offer reference number: CM/PHG/22/5694

FIND A TENDER (FTS) Reference number

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 21 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

CM/PHG/22/5694/00 - Dasatinib

CESW 01/05/2023 – 30/04/2024 – (12 Months)

LSNE 01/05/2023 – 30/04/2024 – (12 Months)

NWLN 01/05/2023 – 30/04/2024 – (12 Months)

CM/PHG/22/5694/01 - Paliperidone Injection:

LSNE 01/05/2023 – 31/05/2024 (13 Months)

NWLN 01/05/2023 – 31/01/2025 (21 months)

Quality Control Technical Sheet

1. The Offeror shall complete the Pharma QC database which is located at <https://www.gov.uk/government/publications/drug-quality-assurance-database-pharmaqc-information>, as detailed in the instructions document 'Drug supplier database'.

Completion and acceptance to this form is undertaken on the Atamis e-Tendering portal under "My Proposals and Quotes".

2. Where the Offeror has indicated that the information published on PharmaQC database applies, it undertakes to each of the Commercial Medicines Unit and the Customers as follows: -
 - 2.1 such information includes all the details requested by this quality control technical sheet;
 - 2.2 it has reviewed such information and warrants to each of the Commercial Medicines Unit and the Customers that it is complete and up to date as at the date the Offeror submits its offer to supply the goods;
 - 2.3 it shall after submitting its offer continue to update such information as and when required.

3. The Offeror acknowledges that any failure to provide the information required by this quality control technical sheet may mean that the Commercial Medicines Unit and/or the Customers will receive insufficient information to assess the Offeror's offer to supply. As a result, the Offeror's offer may be rejected.
4. The Offeror accepts that the specification of the goods shall be determined by reference to the specification of the goods held by the Medicines and Healthcare products Regulatory Agency and to the terms of any contract of supply which may be entered into where the Offeror is appointed to the framework agreement. If there is any inconsistency between the information provided by the Offeror under paragraph 0.1 and either the specification of the goods held by the Medicines and Healthcare products regulatory Agency or the terms of any contract of supply entered into, such specification and terms of any contract of supply entered into shall prevail.
5. The Offeror agrees that it shall acquire no proprietary right or interest in PharmaQC database maintained by the Commercial Medicines Unit.
6. In this quality control technical sheet, "Customers" shall have the meaning given to it in the framework agreement sent to the Offeror with this quality control technical sheet.

Declaration

We hereby declare that we have provided the information requested by the **quality control technical sheet** by causing such information to be published on the PharmaQC database maintained by the Commercial Medicines Unit and agree to comply with the terms set out above.

<https://www.gov.uk/government/publications/drug-quality-assurance-database-pharmacq-information>

Acceptance of this form and the above declaration is undertaken on the Atamis e-Tendering portal under “My Proposals and Quotes”